![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 16.50 | 16.00 | 17.00 | 16.50 | 16.50 | 16.50 | 22,804 | 07:36:58 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 5.81 | 15.05M |
Date | Subject | Author | Discuss |
---|---|---|---|
31/1/2017 20:31 | Well that was a day to forget. Blue is so much better, think about it shares, cars, movies. Although Hunt for Red October wasn't bad.. :) | ![]() 1bokke | |
31/1/2017 18:07 | What would be nice is if some of these celebrities are seen sipping the shakes and munching the snack bars! | misconduct | |
31/1/2017 18:04 | £130 an hour! Me thinks I'll have to turn the table round on this ;-) | elrico | |
31/1/2017 15:03 | But we do know for certain that (at least) two multinational consumer goods companies are looking to produce products using OPTI's IP. Take your pick... Mondelez, Kraft, Coca-Cola, Nestle, Pepsico, P&G, Johnson&Johnson, Mars, Danone, Tata, General Mills, Kellogg's, Unilever, Tate & Lyle, DuPont, GlaxoSmithKline, | ![]() someuwin | |
31/1/2017 14:50 | Just strong rumours at the moment. That's why the share price will rocket when / if we get confirmation. | ![]() someuwin | |
31/1/2017 14:46 | Do we know for sure that tata and P & G are on board, we only have TW's word, are they 100% | neftanikoff | |
31/1/2017 13:02 | With a bit of "Ohara Twist" thrown in | kipper1960 | |
31/1/2017 12:20 | No problem mouse. I would love to know that too but I definitely won't be given any info! So many things coming to the boil now, hopefully we get something soon! I think us LTH deserve it! | primal123 | |
31/1/2017 12:12 | Thanks Primal. Could you drop her a line to ask if we will get an RNS soon on any of the following? Tata P&G Boots Slimfast Nizo VLG DSM J&J (skin) Skin flotation. Have I missed anything? When the news comes it should be exciting....... | ![]() mouse20 | |
31/1/2017 12:04 | I emailed Anna to see if we would get any form of RNS on the presentations this week, the response is below: "We were not planning to releasing the abstracts. ProBiotia is a very scientific conference so the posters are designed for that audience. We gave relatively detailed information on what the abstracts were about in the release on 12 January so I don't really think we need to announce anything else." | primal123 | |
31/1/2017 11:17 | I am in agreement Someuwin; Yes I, too, expect follow-on developments to trigger share price rise; I suppose I'm simply suggesting (as you are): don't expect fireworks this week, or any week for that matter, in absence of an igniter; but then that's what we're all saying - and we're in for the long(ish!) haul. | owenmo | |
31/1/2017 11:08 | Owenmo - there's a world of difference between last year's PR company organised investor presentation, and this year's presentation at a major industry conference... "ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiota focused food and pharma industries. The conference is world renowned as a key meeting place for a community of scientists and business leaders who want to translate science into new products in the growing supplements and ingredients market." Will this lead to a big rise in sp? probably not. But as they've explained, these publications will support the launch of their new cardiovascular products. i.e once they have done the official presentations they can get on and tell the world about their new Cholesterol and blood pressure products. And that SHOULD lead to a big rise in the share price | ![]() someuwin | |
31/1/2017 10:43 | I may be behind the curve publishing this here now, but anyway, this is Berlin on Friday according to the website quoted in an earlier post. SOH is one of only two people given the opportunity to make an oral presentation (i.e. the best two as reviewed by the Science Committee) It starts Friday at 11:15 European time, and they get 15 mins each). Stephen will present his Scientific Frontiers abstract: An assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum LP-LDL in adults with normal to mildly elevated cholesterol OBJECTIVE: This aim of this study was to investigate the cholesterol reducing capacity of Lactobacillus plantarum LP-LDL in 49 healthy adults with normal to mildly elevated cholesterol. LP-LDL was selected after screening 4000 strains for high bile salt hydrolase (BSH) and high in vitro cholesterol reduction activity. Primary efficacy outcomes included effect on blood lipids (TC, LDL-C, HDL-C, TAG) and product safety (inflammatory biomarkers, occurrence of gastrointestinal side effects). Secondary outcomes included blood pressure, immune biomarkers and gut microbiome changes. METHODS: The study was conducted in a parallel, double blind placebo controlled, randomised design. The active group ingested 2×109 CFU encapsulated L. plantarum LP-LDL twice daily for 12 weeks. The placebo group received identical capsules without the probiotic. Samples were provided at baseline, 6, 12 and 16 weeks (washout). RESULTS: LDL-C was significantly lower in the active group with baseline TC<5mM (13.9%, P=0.030; 0-12weeks) and the TC6mM group (36.7%, P=0.045; 0-6weeks) compared to the placebo. Active treatment in the over 60yrs population significantly increased HDL-C levels (14.7%, P=0.03) and reduced TAG (53.9%, P=0.02). A statistically significant reduction in systolic blood pressure was also observed in the active study group (6.6%, P=0.003; 6-12week period). LP-LDL ingestion had no impact on inflammatory biomarkers and gastrointestinal parameters. CONCLUSIONS: The results of this study confirmed the safety of L. plantarum LP-LDL and demonstrated that it can positively impact on cardiovascular risk lipid profiles and blood pressure. Our results, in an unoptimised product, in healthy adults, suggest efficacy similar or greater to 1.5-2.4g/day plant sterols/stanols. There will also be two 'posters' from OPTI (out of 17): 4 – Development of a synergistic synbiotic for Lactobacillus plantarum LP-LDL targeting cholesterol reduction Dr Sofia Kolida, OptiBiotix Health 12 – An assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum LP-LDL in adults with normal to mildly elevated cholesterol Stephen OHara, OptiBiotix Health Best wishes - Mike p.s. I don't know if OPTI will RNS the contents of the presentations in layman's language, but I suspect they might. | ![]() spike_1 | |
31/1/2017 10:42 | A case of deja vu all over again? This time last year witnessed 100p share price in prospect - not least in anticipation of SOH (Feb?) Press Briefing in London Hotel that we all got excited about? (I know I was very tempted to travel for it; a bonus would have been to have met some of you guys) Is there anything in next Friday's presentation not yet in public domain? So, next week, in absence of the all-too-scarce ground-breaking RNS, is it a re-run of "as you were!" next week? | owenmo | |
31/1/2017 10:40 | How good would SOH feel if he could stand up on Friday and say " I'm really pleased that we announced yesterday ... boots... Tata... " hint hint Stephen.. | ![]() 1bokke | |
31/1/2017 10:39 | They do Parob. | elrico | |
31/1/2017 10:38 | just sold my PMO to top up my holding here this morning | ![]() humphries1 | |
31/1/2017 10:35 | OPTI just now on twitter: OptiBiotix Health @OptiBiotix 39s40 seconds ago @GoFigureDiet are listed on page 7 under 'Hot Buys - True Health's top picks' #slimbiome They must read this bulletin board! | ![]() parob | |
31/1/2017 10:34 | Commenting, Stephen O'Hara, CEO of OptiBiotix said: "These publications, at a major conference, will support the launch of a range of cardiovascular products to reduce LDL cholesterol, blood pressure and cardiovascular risk, planned for the spring of 2017. The publications will provide the scientific evidence for sales and marketing literature, which will help with product differentiation and higher margins. In order to provide us with wider coverage of our scientific advances in both the scientific and mainstream news media, we have appointed a specialist scientific PR company, Vane Percy & Roberts to help with this." | ![]() someuwin | |
31/1/2017 10:11 | some, I personally think on-line limits can be deceiving Much prefer to call somebody and actually find out whats available and at what price in the "real" world. Sometimes the maximum will only be 10k shares available, sometimes 20k shares, occasionally 50k shares, sometimes T20 and sometimes only T10 Each to their own though hey :) | ![]() judijudi | |
31/1/2017 10:03 | There's loads of shares available with ALL brokers (depending on how much you are prepared to pay). I post the ONLINE quote limits as a rough and ready indication of demand. | ![]() someuwin | |
31/1/2017 09:58 | Loads of shares available with my broker | ![]() judijudi | |
31/1/2017 09:51 | Can get an online quote for £2k. but not £3k. | ![]() someuwin |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions